The United Kingdom and the United States have agreed to a major trade agreement that will keep no tariffs on British medicine exports going into the American market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to boost expenditure on medicines through the public health system. This pledge secures that import taxes on these crucial products will remain at nothing for a duration of the next three years.
This deal is in response to earlier threats to significantly raise tariffs on patented drug imports, with figures mentioned as high as 100%.
"This deal between the United Kingdom bolsters the global environment for cutting-edge drugs and introduces long-overdue equity to transatlantic drug exports," a statement noted.
Trade Significance
Pharmaceuticals are one of the Britain's biggest goods shipped to the America, which is clearly the largest buyer for major companies like GSK and AstraZeneca.
Trade data show that in the 12 months to the end of the third quarter, the UK sold medicines valued at £11.1bn to the US. This value represented a significant portion of all goods exports in that timeframe.
"This deal safeguards jobs, stimulates capital expenditure and paves the way for the UK to become a global hub for life sciences," the Business and Trade Secretary stated.
Specific UK Commitments
The deal includes several notable pledges from the UK:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it considers new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a goal to increase total public funding on medicines from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The sum pharmaceutical firms must refund to the NHS to control costs will be limited at 15%. In the past, repayments exceeded 20%.
Industry Background
The deal comes amid a protracted row between the pharmaceutical industry and the ministers over spending levels and NHS adoption.
The disagreement were intensified by claims that US customers were charged significantly more for the same drugs than people in the UK and Europe.
Recently, several significant manufacturing plans in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been directed toward projects in the United States.
The Science Minister stated that the NHS must invest a greater share on medicines, noting that its expenditure on drugs had decreased as a share of its total funding over the previous ten-year period.
